Nifty
Sensex
:
:
11937.65
40707.31
40.85 (0.34%)
162.94 (0.40%)

Pharmaceuticals & Drugs - Global

Rating :
79/99  (View)

BSE: 524804 | NSE: AUROPHARMA

806.20
5.90 (0.74%)
21-Oct-2020 | 4:02PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  803.00
  •  808.95
  •  792.00
  •  800.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2788840
  •  22483.63
  •  967.50
  •  288.85

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 47,185.64
  • 15.86
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 49,905.46
  • 0.37%
  • 2.68

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 52.01%
  • 0.95%
  • 9.66%
  • FII
  • DII
  • Others
  • 23.01%
  • 13.60%
  • 0.77%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.09
  • 10.86
  • 11.95

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.58
  • 8.82
  • 5.22

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.58
  • 7.06
  • 5.55

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.68
  • 17.11
  • 15.58

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.19
  • 3.94
  • 2.87

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.00
  • 11.78
  • 10.31

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
5,925
5,445
9%
6,158
5,292
16%
5,895
5,270
12%
5,600
4,751
18%
Expenses
4,667
4,298
9%
4,842
4,235
14%
4,687
4,183
12%
4,460
3,765
18%
EBITDA
1,257
1,146
10%
1,316
1,057
24%
1,208
1,086
11%
1,140
986
16%
EBIDTM
21%
21%
14%
20%
20%
21%
20%
21%
Other Income
116
16
633%
33
32
1%
31
64
-52%
21
26
-21%
Interest
21
50
-58%
32
50
-36%
37
48
-22%
41
35
16%
Depreciation
256
241
6%
232
187
25%
250
163
53%
243
164
49%
PBT
1,096
859
28%
1,097
817
34%
939
914
3%
864
787
10%
Tax
304
228
33%
229
231
-1%
233
205
14%
224
175
28%
PAT
793
631
26%
868
586
48%
706
710
-1%
639
611
5%
PATM
13%
12%
7%
11%
12%
13%
11%
13%
EPS
13.53
10.77
26%
14.82
10.00
48%
12.05
12.11
0%
10.91
10.43
5%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
23,579
23,099
19,564
16,463
14,910
13,795
12,121
8,100
5,855
4,627
4,381
Net Sales Growth
14%
18%
19%
10%
8%
14%
50%
38%
27%
6%
 
Cost Of Goods Sold
11,985
8,721
7,886
6,086
5,911
5,612
5,100
3,276
2,730
2,304
1,964
Gross Profit
11,594
14,378
11,677
10,377
8,999
8,182
7,021
4,824
3,125
2,323
2,418
GP Margin
49%
62%
60%
63%
60%
59%
58%
60%
53%
50%
55%
Total Expenditure
18,657
18,234
15,612
12,691
11,475
10,607
9,557
5,966
4,994
4,066
3,418
Power & Fuel Cost
-
588
557
471
437
419
360
350
325
232
208
% Of Sales
-
3%
3%
3%
3%
3%
3%
4%
6%
5%
5%
Employee Cost
-
3,219
2,585
2,131
1,768
1,543
1,302
802
663
536
425
% Of Sales
-
14%
13%
13%
12%
11%
11%
10%
11%
12%
10%
Manufacturing Exp.
-
2,331
2,038
1,611
1,310
1,256
1,023
772
623
543
512
% Of Sales
-
10%
10%
10%
9%
9%
8%
10%
11%
12%
12%
General & Admin Exp.
-
1,321
1,007
1,068
997
686
666
283
198
131
120
% Of Sales
-
6%
5%
6%
7%
5%
6%
4%
3%
3%
3%
Selling & Distn. Exp.
-
1,525
1,123
1,026
848
902
879
360
306
208
142
% Of Sales
-
7%
6%
6%
6%
7%
7%
4%
5%
4%
3%
Miscellaneous Exp.
-
530
416
299
204
188
227
123
149
112
142
% Of Sales
-
2%
2%
2%
1%
1%
2%
2%
3%
2%
1%
EBITDA
4,922
4,864
3,952
3,772
3,434
3,188
2,564
2,134
861
561
963
EBITDA Margin
21%
21%
20%
23%
23%
23%
21%
26%
15%
12%
22%
Other Income
200
192
155
102
116
204
97
22
29
25
71
Interest
131
305
263
78
67
257
160
310
267
277
65
Depreciation
981
967
668
558
428
392
333
313
249
201
172
PBT
3,996
3,784
3,177
3,238
3,056
2,743
2,168
1,533
374
108
799
Tax
989
914
727
818
760
721
597
363
83
-89
225
Tax Rate
25%
24%
24%
25%
25%
26%
28%
24%
22%
42%
29%
PAT
3,006
2,846
2,362
2,420
2,297
2,024
1,576
1,173
294
-124
563
PAT before Minority Interest
3,007
2,845
2,362
2,420
2,296
2,022
1,571
1,169
291
-124
563
Minority Interest
0
1
0
0
0
2
5
4
2
1
0
PAT Margin
13%
12%
12%
15%
15%
15%
13%
14%
5%
-3%
13%
PAT Growth
18%
20%
-2%
5%
13%
28%
34%
299%
338%
-122%
 
EPS
51.31
48.58
40.31
41.30
39.20
34.54
26.89
20.02
5.02
-2.11
9.62

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
16,810
13,891
11,680
9,372
7,287
5,156
3,750
2,606
2,340
2,445
Share Capital
59
59
59
59
59
29
29
29
29
29
Total Reserves
16,752
13,832
11,622
9,313
7,228
5,127
3,721
2,577
2,311
2,416
Non-Current Liabilities
566
336
594
102
584
1,592
1,494
1,225
967
645
Secured Loans
0
180
451
178
380
774
1,101
1,084
862
450
Unsecured Loans
0
0
0
4
363
588
178
64
103
74
Long Term Provisions
75
47
56
39
23
24
9
9
4
3
Current Liabilities
11,387
12,043
8,666
6,606
7,840
6,136
4,220
3,431
2,915
2,768
Trade Payables
2,545
2,677
2,373
2,155
2,457
2,051
1,351
964
660
776
Other Current Liabilities
2,875
2,545
1,967
1,287
1,578
1,365
388
151
580
699
Short Term Borrowings
5,422
6,573
4,031
2,903
3,673
2,502
2,355
2,236
1,608
1,235
Short Term Provisions
545
247
294
261
133
218
127
80
66
58
Total Liabilities
28,763
26,271
20,942
16,082
15,714
12,910
9,490
7,273
6,232
5,868
Net Block
9,396
8,475
6,521
4,834
4,180
3,706
2,722
2,639
2,195
1,739
Gross Block
12,441
10,498
7,895
5,635
4,570
5,446
4,183
3,763
3,086
2,438
Accumulated Depreciation
3,045
2,023
1,374
802
390
1,740
1,461
1,125
892
699
Non Current Assets
12,351
10,907
8,764
6,875
5,420
4,611
3,859
3,136
2,968
2,547
Capital Work in Progress
1,986
1,668
1,583
1,458
848
370
257
168
516
583
Non Current Investment
555
360
312
246
123
0
20
22
20
38
Long Term Loans & Adv.
377
364
262
256
237
455
789
238
108
111
Other Non Current Assets
37
39
87
81
32
30
18
19
0
1
Current Assets
16,412
15,365
12,178
9,206
10,294
8,299
5,631
4,137
3,264
3,321
Current Investments
0
0
0
0
0
20
0
0
19
0
Inventories
7,700
7,246
5,858
4,331
4,056
3,611
2,368
1,924
1,546
1,455
Sundry Debtors
4,315
3,414
3,080
2,765
4,607
3,539
2,637
1,597
1,240
1,231
Cash & Bank
2,842
1,957
1,262
513
800
469
179
208
71
187
Other Current Assets
1,555
1,920
1,223
1,085
831
660
448
408
389
448
Short Term Loans & Adv.
1,066
828
754
512
367
388
237
208
217
359
Net Current Assets
5,026
3,322
3,512
2,601
2,454
2,162
1,411
706
349
553
Total Assets
28,763
26,271
20,942
16,082
15,714
12,910
9,490
7,273
6,232
5,868

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
4,381
1,622
1,955
3,279
1,420
1,237
646
275
326
335
PBT
3,743
3,091
3,241
3,061
2,744
2,168
1,533
374
108
799
Adjustment
1,091
811
535
409
488
406
515
442
387
198
Changes in Working Capital
277
-1,510
-1,123
583
-1,079
-842
-1,057
-422
-128
-469
Cash after chg. in Working capital
5,111
2,392
2,653
4,052
2,152
1,732
990
394
367
527
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-730
-770
-699
-774
-733
-496
-344
-119
-41
-192
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-1,568
-2,877
-1,927
-1,787
-1,445
-1,398
-819
-246
-563
-599
Net Fixed Assets
-607
-799
-771
-1,092
125
-534
-141
-224
-376
-396
Net Investments
-181
-372
-286
-499
-171
-140
-165
-79
-136
-122
Others
-780
-1,706
-870
-196
-1,400
-724
-513
57
-51
-81
Cash from Financing Activity
-1,947
1,919
864
-1,915
365
93
118
108
119
407
Net Cash Inflow / Outflow
866
664
892
-424
340
-68
-55
137
-118
143
Opening Cash & Equivalents
1,876
1,210
318
743
404
148
203
66
184
45
Closing Cash & Equivalent
2,747
1,876
1,210
320
744
461
148
203
66
184

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
287
237
199
160
124
88
64
45
40
42
ROA
10%
10%
13%
14%
14%
14%
14%
4%
-2%
11%
ROE
19%
18%
23%
28%
33%
35%
37%
12%
-5%
26%
ROCE
19%
18%
23%
25%
27%
27%
27%
11%
1%
19%
Fixed Asset Turnover
4.12
2.13
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
Receivable days
30
61
65
89
107
92
94
86
95
89
Inventory Days
58
122
113
101
100
89
95
106
116
104
Payable days
53
60
68
76
82
67
71
58
65
71
Cash Conversion Cycle
35
123
110
115
125
113
117
134
147
122
Total Debt/Equity
0.33
0.50
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
Interest Cover
13
13
43
47
12
15
6
2
0
13

News Update


  • Aurobindo Pharma to acquire entire stake in MViyeS
    19th Oct 2020, 11:59 AM

    MViyeS is holding 32.18% shareholding in Eugia Pharma Specialities, a joint venture company in which the Company is holding 67.82%

    Read More
  • Aurobindo Pharma collaborates with CSIR to develop COVID-19 vaccine
    16th Sep 2020, 08:50 AM

    Aurobindo will undertake clinical development and commercialization of the vaccines

    Read More
  • DBT- BIRAC supports Aurobindo Pharma’s COVID-19 vaccine development
    15th Sep 2020, 16:34 PM

    Government of India has facilitated the establishment of the r-VSV vaccine manufacturing platform for the first time in India

    Read More
  • Aurobindo Pharma reports 23% rise in Q1 consolidated net profit
    13th Aug 2020, 11:56 AM

    Total consolidated income of the company increased by 10.62% at Rs 6,040.37 crore for Q1FY21

    Read More
  • Aurobindo Pharma - Quarterly Results
    12th Aug 2020, 19:39 PM

    Read More
  • Aurobindo Pharma working on developing several viral vaccines including one for COVID-19
    7th Aug 2020, 13:22 PM

    During the year (FY20), the company has further strengthened its presence in the vaccines segment through the acquisition of R&D assets from Profectus Biosciences through Auro Vaccines

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.